tirzepatide mash phase 3 Lessons from incretin-based therapy in and obesity Tirzepatide in metabolic dysfunction-associated steatotic – tirzepatide nash phase 3 In

However, because they slow gut motility, they may increase susceptibility in some individualsparticularly those with existing risk factors such as IBS, constipation, or prior gastrointestinal infections

To overcome these limitations, a number of pharmacological approaches have been developed over the past decades, but these drugs are generally of fairly limited efficacy, expensive and can in some cases cause significant side effects

Take charge of your health journey and work with your healthcare team to achieve your goals

GLP-1 slows gastric emptying (how quickly food leaves your stomach), helping you feel fuller for longer

The tirzepatide molecule itself has extensive clinical backing through the SURMOUNT and SURPASS trial programs